Long-term lanreotide treatment in six patients with congenital hyperinsulinism

Hormone Research in Paediatrics

Volumn 78, Issue 2, 2012, Pages 106-112

  Khnen, Peter ^a   Marquard, Jan ^b   Ernert, Andrea ^a   Meissner, Thomas ^b   Raile, Klemens ^a   Wannenmacher, Gertrud ^c   Blankenstein, Oliver ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Beta cell; Congenital hyperinsulinism; Insulin; Lanreotide; Treatment

Indexed keywords

ANGIOPEPTIN; DIAZOXIDE; GLUCOSE; OCTREOTIDE;

BODY WEIGHT; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG DOSE TITRATION; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INFANT; INJECTION SITE INDURATION; LABORATORY TEST; LONG TERM CARE; NECROTIZING ENTEROCOLITIS; NUCLEOTIDE SEQUENCE; PANCREAS RESECTION; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA OF INFANCY; PRIORITY JOURNAL; SIDE EFFECT; TACHYPHYLAXIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; CHILD, PRESCHOOL; CONGENITAL HYPERINSULINISM; FEMALE; HUMANS; INFANT; MALE; PEPTIDES, CYCLIC; SOMATOSTATIN; TIME FACTORS;

EID: 84866480714     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000341525     Document Type: Conference Paper

References (30)

1. Hussain K: Insights in congenital hyperinsulinism. Endocr Dev 2007; 11: 106-121.
2. Mohnike K, Blankenstein O, Christesen HT, De Lonlay J, Hussain K, Koopmans KP, Minn H, Mohnike W, Mutair A, Otonkoski T, Rahier J, Ribeiro M, Schoenle E, Fekete CN: Proposal for a standardized protocol for F-DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res 2006; 66: 40-42.
3. Hussain K: Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy. Horm Res 2008; 69: 2-13.
4. Beltrand J, Caquard M, Arnoux JB, Laborde K, Velho G, Verkarre V, Rahier J, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ, de Lonlay P: Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care 2012; 35: 198-203.
5. Pierro A, Nah SA: Surgical management of congenital hyperinsulinism of infancy. Semin Pediatr Surg 2011; 20: 50-53.
6. Meissner T, Wendel U, Burgard P, Schaetzle S, Mayatepek E: Long-term follow-up of 114 patients with congenital hyperinsulinism. Eur J Endocrinol 2003; 149: 43-51.
7. Beltrand J, Caquard M, Arnoux JB, Laborde K, Velho G, Verkarre V, Rahier J, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ, de Lonlay P: Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism. Diabetes Care 2012; 35: 198-203.
8. Cherian MP, Abduljabbar MA: Persistent hyperinsulinemic hypoglycemia of infancy: long-term outcome following 95% pancreatectomy. J Pediatr Endocrinol Metab 2005; 18: 1441-1448.
9. De Lonlay P, Fournet JC, Touati G, Groos MS, Martin D, Sevin C, Delagne V, Mayaud C, Chigot V, Sempoux C, Brusset MC, Laborde K, Bellane-Chantelot C, Vassault A, Rahier J, Junien C, Brunelle F, Nihoul-Fekete C, Saudubray JM, Robert JJ: Heterogeneity of persistent hyperinsulinaemic hypoglycaemia. A series of 175 cases. Eur J Pediatr 2002; 161: 37-48.
10. Kapoor RR, Flanagan SE, James C, Shield J, Ellard S, Hussain K: Hyperinsulinaemic hypoglycaemia. Arch Dis Child 2009; 94: 450-457.
11. Aynsley-Green A, Hussain K, Hall J, Saudubray JM, Nihoul-Fekete C, De Lonlay-Debeney P, Brunelle F, Otonkoski T, Thornton P, Lindley KJ: Practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed 2000; 82:F98-F107.
12. Bas F, Darendeliler F, Demirkol D, Bundak R, Saka N, Gunoz H: Successful therapy with calcium channel blocker (nifedipine) in persistent neonatal hyperinsulinemic hypoglycemia of infancy. J Pediatr Endocrinol Metab 1999; 12: 873-878.
13. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ: Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs 2009; 69: 2207-2226.
14. Kelly P, Maher KT, Chew SL, Monson JP, Grossman AB, Jenkins PJ: A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide autogel in patients with acromegaly previously treated with octreotide. Endocr Pract 2010; 16: 191-197.
15. Ruszniewski P, Ish-Shalom S, Wymenga M, O'Toole D, Arnold R, Tomassetti P, Bax N, Caplin M, Eriksson B, Glaser B, Ducreux M, Lombard-Bohas C, de Herder WW, Delle Fave G, Reed N, Seitz JF, Van Cutsem E, Grossman A, Rougier P, Schmidt W, Wiedenmann B: Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology 2004; 80: 244-251.
16. Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B: Control of IGF-I levels with titrated dosing of lanreotide autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 2008; 69: 299-305.
17. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ: Oneyear follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide autogel. Clin Endocrinol (Oxf) 2004; 60: 734-740.
18. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM: Effectiveness and tolerability of 3-year lanreotide autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 2006; 64: 209-214.
19. Hu M, Tomlinson B: Pharmacokinetic evaluation of lanreotide. Expert Opin Drug Metab Toxicol 2010; 6: 1301-1312.
20. Carel JC, Blumberg J, Bougeard-Julien M, Rochiccioli P, Chaussain JL, Tauber M: Long-acting lanreotide in adolescent girls with constitutional tall stature. Horm Res 2009; 71: 228-236.
21. Kuehnen P, Marquard J, Meissner T, Blankenstein O: Successful long-term treatment of congenital hyperinsulinism with lanreotide: 8th LWPES/ESPE Joint Meeting, in collaboration with APEG, APPES, JSPE and SLEP, New York, N.Y. Horm Res 2009; 72(suppl 73):158.
22. Modan-Moses D, Koren I, Mazor-Aronovitch K, Pinhas-Hamiel O, Landau H: Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab 2011; 96: 2312-2317.
23. Koh TH, Eyre JA, Aynsley-Green A: Neonatal hypoglycaemia -the controversy regarding definition. Arch Dis Child 1988; 63: 1386-1388.
24. Hartman AF, Jaundon JC: Hypoglycaemia. J Pediatr 1937; 11: 1-36.
25. Rozance PJ, Hay WW Jr: Describing hypoglycemia -definition or operational threshold? Early Hum Dev 2010; 86: 275-280.
26. Alkalay AL, Sarnat HB, Flores-Sarnat L, Elashoff JD, Farber SJ, Simmons CF: Population meta-analysis of low plasma glucose thresholds in full-term normal newborns. Am J Perinatol 2006; 23: 115-119.
27. Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellanne-Chantelot C, Valayannopoulos V, Brassier A, Kayirangwa H, Barbier V, Broissand C, Fabreguettes JR, Charron B, Thalabard JC, de Lonlay P: Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol 2012; 166: 333-339.
28. Straussman S, Levitsky LL: Neonatal hypoglycemia. Curr Opin Endocrinol Diabetes Obes 2010; 17: 20-24.
29. Glaser B, Landaw H: Long-term treatment with the somatostatin analogue SMS 201-995: alternative to pancreatectomy in persistent hyperinsulinaemic hypoglycaemia of infancy. Digestion 1990; 45(suppl 1):27-35.
30. Thornton PS, Alter CA, Katz LE, Baker L, Stanley CA: Short-and long-term use of octreotide in the treatment of congenital hyperinsulinism. J Pediatr 1993; 123: 637-643.